TTrialPathMatch Me to Trials
← Back to trials
RecruitingKnee Osteoarthritis

Platelet-rich Plasma in Symptomatic Knee Osteoarthritis

Eligible age

40–79 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Intro: Platelet rich plasma (PRP) is largely used in various musculoskeletal disorders such as chronic tendinopathies but also osteoarthritis (OA). Several therapeutic trials evaluating the effectiveness of intra-articular PRP injections in knee OA as well as meta-analyses have already been published. Most of them have compared PRP to Hyaluronic Acid (HA). Their design was very heterogeneous in terms of PRP characteristics and injection protocol. Moreover, the number of patients included was often very low. Only few studies have compared PRP to placebo (physiological serum) and presented the same methodological limitations (limited number of patients, heterogeneous protocols in terms of number and frequency of injections, characteristics of PRP, etc.). Given the insufficient level of evidence related to these limitations, PRP injections are not recommended in the treatment of symptomatic knee OA by the main scientific societies such as American College of Rheumatology (ACR), Osteoarthritis Research Society International (OARSI), American Academy of Orthopedic Surgeons (AAOS) and French Society of Rheumatology (SFR). Experts in the field agree on the need for a placebo-controlled trial with hihg methodological quality and simple design in order to conclude with a good level of evidence to the benefit or not of this new therapeutic weapon in symptomatic knee osteoarthritis of moderate radiographic severity.

Sponsor: Assistance Publique - Hôpitaux de Paris

You may qualify if…

  • ✓ Age between 40 and 79
  • ✓ Symptomatic knee OA according to ACR criteria evolving for more than 3 months
  • ✓ Predominantly femoro-tibial pain
  • ✓ KL 2 or 3 on femorotibial compartment on X-rays of less than 6 months
  • ✓ ENS ≥ 40/100 (with or without usual analgesic treatments)
  • ✓ Failures or contraindications to conventional treatments (analgesics, NSAIDs)
  • ✓ Patient able to understand the requirements of the trial and having signed a free and informed consent before entering the study
  • ✓ Patient able to read and understand written instructions

You may not qualify if…

  • ✕ Other pathologies of the lower limbs interfering with the evaluation of knee osteoarthritis (symptomatic hip OA, Lumbar pain…)
  • ✕ Symptomatic contralateral knee OA with NRS ≥ 40/100
  • ✕ Predominant patellofemoral symptoms
  • ✕ Radiographic knee OA stage 1 or 4 of KL
  • ✕ Predominant radiographic patellofemoral OA
  • ✕ History of target knee surgery with material
  • ✕ History of inflammatory or microcrystalline rheumatism
  • ✕ History of fibromyalgia

Source: ClinicalTrials.gov · NCT05378815 · last updated 2025-07-11

Platelet-rich Plasma in Symptomatic Knee Osteoarthritis · TrialPath